Brinzolamide/Timolol: In Open-Angle Glaucoma and Ocular Hypertension

▲ Brinzolamide 1%/timolol 0.5% fixed combination (brinzolamide/timolol) is a twice-daily eyedrops suspension comprising the carbonic anhydrase-II inhibitor brinzolamide and the β-adrenergic receptor antagonist timolol. ▲ Brinzolamide/timolol produced clinically relevant reductions in mean intraocula...

Full description

Saved in:
Bibliographic Details
Published in:Drugs & aging 2009-01, Vol.26 (5), p.437-446
Main Authors: Croxtall, Jamie D., Scott, Lesley J.
Format: Article
Language:English
Subjects:
Adis Drug Profile
Adrenergic beta-Antagonists - administration & dosage
Adrenergic beta-Antagonists - adverse effects
Adrenergic beta-Antagonists - therapeutic use
Biological and medical sciences
Brinzolamide
Carbonic Anhydrase Inhibitors - administration & dosage
Carbonic Anhydrase Inhibitors - adverse effects
Carbonic Anhydrase Inhibitors - therapeutic use
Clinical Trials as Topic
Development and progression
Dosage and administration
Drug Combinations
Drug therapy
Drug therapy, Combination
Eye
Geriatrics/Gerontology
Glaucoma and intraocular pressure
Glaucoma, Open-Angle - drug therapy
Health aspects
Humans
Internal Medicine
Intraocular Pressure - drug effects
Medical sciences
Medicine
Medicine & Public Health
Movement disorders
Ocular Hypertension - drug therapy
Open-angle glaucoma
Ophthalmology
Pharmacology. Drug treatments
Pharmacology/Toxicology
Pharmacotherapy
Risk factors
Sulfonamides - administration & dosage
Sulfonamides - adverse effects
Sulfonamides - therapeutic use
Thiazines - administration & dosage
Thiazines - adverse effects
Thiazines - therapeutic use
Timolol - administration & dosage
Timolol - adverse effects
Timolol - therapeutic use
Timolol maleate
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:▲ Brinzolamide 1%/timolol 0.5% fixed combination (brinzolamide/timolol) is a twice-daily eyedrops suspension comprising the carbonic anhydrase-II inhibitor brinzolamide and the β-adrenergic receptor antagonist timolol. ▲ Brinzolamide/timolol produced clinically relevant reductions in mean intraocular pressure (IOP) from baseline and was more effective than brinzolamide or timolol monotherapy in lowering IOP in a 6-month, randomized, phase III trial in patients with open-angle glaucoma or ocular hypertension (n = 523). The proportion of patients achieving a mean IOP of
ISSN:1170-229X
1179-1969
DOI:10.2165/00002512-200926050-00007